{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:09:28Z","timestamp":1790809768359,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jaad.2020.04.087","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T13:37:26Z","timestamp":1587994646000},"page":"477-485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris"],"prefix":"10.1016","volume":"83","author":[{"given":"Lawrence","family":"Eichenfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fragasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mazzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.04.087_bib1","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1038\/nrdp.2015.29","article-title":"Acne vulgaris","volume":"1","author":"Moradi Tuchayi","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaad.2020.04.087_bib2","first-page":"13","article-title":"The epidemiology of acne vulgaris in late adolescence","volume":"7","author":"Lynn","year":"2016","journal-title":"Adolesc Health Med Ther"},{"key":"10.1016\/j.jaad.2020.04.087_bib3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.mce.2017.09.009","article-title":"Androgens and androgen receptor action in skin and hair follicles","volume":"465","author":"Ceruti","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jaad.2020.04.087_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/CCID.S137794","article-title":"Adult-onset acne: prevalence, impact, and management challenges","volume":"11","author":"Rocha","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3 Suppl 1","key":"10.1016\/j.jaad.2020.04.087_bib5","first-page":"s30","article-title":"Androgens, androgen receptors and the skin: from the laboratory to the clinic with emphasis on clinical and therapeutic implications","volume":"19","author":"Del Rosso","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.04.087_bib6","first-page":"1005","article-title":"Androgens have forgotten and emerging roles outside of their reproductive functions, with implications for diseases and disorders","volume":"1","author":"Dart","year":"2014","journal-title":"J Endocr Disord"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.087_bib7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.087_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/CCID.S114830","article-title":"Hormonal treatment of acne vulgaris: an update","volume":"9","author":"Elsaie","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaad.2020.04.087_bib9","first-page":"412","article-title":"Cortexolone 17\u03b1-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in\u00a0vitro","volume":"18","author":"Rosette","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.04.087_bib10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1039\/C4MD00049H","article-title":"A full conformational characterization of antiandrogen cortexolone-17\u03b1-propionate and related compounds through theoretical calculations and nuclear magnetic resonance spectroscopy","volume":"5","author":"Ferraboschi","year":"2014","journal-title":"Med Chem Commun"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.087_bib11","first-page":"563","article-title":"Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with facial acne vulgaris: an open-label phase 2a study","volume":"18","author":"Mazzetti","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.087_bib12","first-page":"570","article-title":"A phase IIb, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial acne","volume":"18","author":"Mazzetti","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.04.087_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2020.0465","article-title":"Efficacy and safety of clascoterone topical cream, 1% (CB-03-01) in patients with acne: results from two randomized Phase III clinical trials","author":"Hebert","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.087_bib14","author":"Blume-Peytavi"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220307039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220307039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:55:01Z","timestamp":1759272901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220307039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0190962220307039"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.087","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}